Introduction
Methylation of cytosine residues at the 5 position occurs on opposite DNA strands in the palindromic sequence, CpG. These CpG residues are predominately methylated in CG-poor regions of the genome, whereas CGrich regions, called 'CpG islands', remain largely unmethylated (Cross et al., 1994) . More than half of all mammalian genes contain CpG islands overlapping their promoter sequences (Bird, 1986; Gardiner-Garden and Frommer, 1987; Larsen et al., 1992) .
These CpG islands are unmethylated in normal cells, except for imprinted genes (Birger et al., 1999) and for genes on the inactive X chromosome (Alcalay and Toniolo, 1988) . In cancer, there is a generalized hypomethylation of the genome accompanied by region-specific hypermethylation. Hypermethylation of CpG islands in the promoter region of tumor-suppressor genes has been demonstrated to serve as an alternative mechanism for their inactivation in oncogenesis (Jones, 1996; Jones and Laird, 1999) . Several tumor-suppressor genes, such as Rb (Stirzaker et al., 1997) , VHL (Herman et al., 1994) , E-cadherin (Yoshiura et al., 1995) , p15 (Dodge et al., 1998) and p16 (Akanuma et al., 1999) have been reported to be inactivated by 'CpG island' DNA hypermethylation in different human cancer types (Herman et al., 1994; Glavac et al., 1996; Baylin et al., 1998; Guo et al., 2000) .
An inverse relation between CpG methylation in a gene's promoter region and its transcriptional activity has been well documented (Razin and Cedar, 1991; Yeivin and Razin, 1993; Kass et al., 1997) . Whereas methylated cytosine residues do not affect base pairing, they can alter protein-DNA interactions by protruding into the DNA major groove. DNA methylation can not only reduce the binding affinity of sequence-specific transcription factors (Tate and Bird, 1993) but can also recruit methyl-DNA-binding proteins that act as transcriptional repressors (Pawlak et al., 1991; Jost and Hofsteenge, 1992; Zhang et al., 1993) . Five methylCpG-binding proteins (MeCP2, MBD1, MBD2, MBD3 and MBD4) have been identified in vertebrates (Ballestar and Wolffe, 2001) . These proteins, with the exception of MBD2 and MBD3, share little sequence homology outside their methyl-DNA-binding domain (MBD) . It has been established that MeCP2, MBD1 and MBD2 are all involved in histone deacetylasedependent repression (Ng and Bird, 2000) . Deacetylation of histones is associated with the generation of a 'closed' chromatin structure and transcriptional inactivity. Inhibitors of the maintenance DNA methyltransferase (DNMT) have been used to study the effect of methylation on gene expression. 5 0 -azacytidine and its deoxy-derivative, 5-aza-2 0 deoxycytidine, trap the DNMT enzyme in a covalent complex with the DNA. This results in a progressive loss of DNA methylation with each successive round of cell division. The Syk protein tyrosine kinase (PTK) along with Zap-70 protein tyrosine kinase comprise a family of cytoplasmic kinases that play important roles in signal transduction pathways activated by the engagement of hematopoietic cell surface receptors (Gulbins et al., 1994; Sieh et al., 1994; Takata et al., 1994; Bolen, 1995; Kurosaki et al., 1995; Nagai et al., 1995; Sidorenko et al., 1995; Chan and Shaw, 1996; Deckert et al., 1996; Latour et al., 1996; Law et al., 1996; Panchamoorthy et al., 1996; Takata and Kurosaki, 1996; Bolen and Brugge, 1997; Harmer and DeFranco, 1997; Li et al., 1997; Qin et al., 1998) . SYK also plays a pivotal role in B-cell development (Cheng et al., 1995; Turner et al., 1997; Cornall et al., 2000) .
SYK has been shown to be highly expressed in breast ductal epithelial cells, but this expression is decreased in invasive breast carcinomas and breast cancer cell lines (Coopman et al., 2000; Stewart and Pietenpol, 2001 ). This silencing of SYK expression was demonstrated to result from hypermethylation of the CpG island in the Syk promoter (Yuan et al., 2001) . The Syk promoter was found to be hypermethylated in 32% (12/37) of unselected breast tumors and 30% (6/20) of tested breast cancer cell lines. This hypermethylation of the Syk promoter correlated with absence of SYK expression. Treatment of breast cancer cell lines with a methylation inhibitor, 5-aza-2 0 -deoxycytidine, led to reactivation of Syk expression in SYK-negative cells as measured by RT-PCR (Yuan et al., 2001) .
The regulation of SYK expression in T cells is complex. Both src family kinases and SYK/ZAP family kinases are involved in propagating the signals necessary for T-cell development, activation and differentiation. Syk is expressed at higher levels in the thymus and is downregulated in the periphery (Chan et al., 1994) . Intracellular staining for SYK expression in thymocytes from both mice and humans demonstrated that SYK is expressed at the highest levels during early developmental stages of T-cell ontogeny and is downregulated after differentiation of CD3/T-cell antigen (TCR) À cortical thymocytes into CD3/TCR + medullary thymocytes. These results suggest that SYK may be involved in propagation of CD3/TCR-independent signals as well (Chu et al., 1999) . SYK-deficient mice have no reported ab-T-cell defect, although a subset of gd T cells is impaired in their development (Mallick-Wood et al., 1996) .
Expression levels of SYK are likely to play an important role for the competency of our immune system and may also play a role in oncogenesis. Therefore, a better understanding of the regulation of Syk expression is of paramount importance. The purpose of the present study is to analyse the Syk promoter region in human leukemic cells, thymocytes and peripheral blood lymphocytes. Our results demonstrate that methylation of the Syk promoter CpG island (GenBank # Z 65706) regulates SYK expression in Tlineage leukemia cells. Syk promoter methylation was also seen in a bone marrow sample from a T-lineage acute lymphoblastic leukemia (ALL) patient, suggesting a potential role for Syk promoter methylation in Tlineage ALL.
Results and discussion
Sequence analysis of the region surrounding the first SYK exon demonstrates a high GC content and a potential initiator element Two restriction fragments, a 2.7 kb HindIII and a 12.1 kb EcoRI, containing Syk 5 0 untranslated region were isolated from a genomic P1 Syk clone. Complete sequencing of these fragments demonstrated that the 12.1 kb EcoRI fragment contained approximately 9.5 kb of upstream Syk sequence (Figure 1 ), whereas the 2.7 kb fragment contained 776 bases of upstream sequence. A potential initiator sequence, CCACTTT, was identified 241 bases upstream of the published Syk cDNA sequence (HUMPTK, GenBank, Accession # L 28824). No canonical TATA region was identified. This sequence was highly GC rich and contained several SP1-binding sites. Analysis of Syk cDNAs and ESTs in GenBank identified the EST with the longest 5 0 sequence (GenBank Accession # BE 791259), which extends 160 bp past the published HUMPTK Syk cDNA (Figure 1 , sequence underlined).
Transient transfection assays in Daudi cells demonstrated promoter activity within a 348 bp BstXI-BsrBI fragment and allowed identification of a potential negative regulatory element Four restriction fragments: a 352 bp BstX1-BsrBI fragment, a 575 bp SpeI-BsrBI fragment, a 834 bp HindIII-BsrBI fragment and an 2177 bp EcoRV-BsrBI fragment were cloned into a luciferase plasmid, pGL3-Basic plasmid (Figures 1 and 2a) . These Syk promoter-luciferase plasmids were transiently transfected into Daudi cells and the luciferase activity was measured 2 days later. The smallest 352 bp BstXI-BsrBI piece demonstrated an approximate 18-fold (average of two different experiments conducted in triplicate) increase in the luciferase activity over the parental pGL3-Basic plasmid (Figure 2 ). Extending the construct to include additional 5 0 material demonstrated the presence of a negative regulatory element between an SpeI and a HindIII site. Inclusion of this region in our constructs resulted in a 23% decrease in luciferase activity. Extension of our constructs further to an EcoRV site had little additional effect on promoter activity in these transient transfection assays. We next performed a comparison of the Syk upstream sequence with GenBank sequences utilizing NCBI (National Center for Biotechnology Information) Blast (Basic Local Alignment Search Tool) analysis. We obtained a near-perfect match for a portion of our sequence with a previously isolated CpG island (GenBank # Z 65706). This CpG island sequence was obtained from a genomic MseI restriction fragment isolated based on the presence of hypomethylated CpG residues (Cross et al., 1994) . We manually inspected the sequence surrounding the Syk first exon and observed that there is a GC-rich region containing multiple CpG dinucleotides surrounding the first exon of Syk. This CpG island region is approximately 1.1 kb length and extends approximately 600 bases upstream and 420 bases downstream of the first Syk exon.
Bisulfite sequence analysis of the CpG island in the Syk promoter region reveals dense methylation in T-lineage leukemic cells
We were interested in studying methylation of the 5 0 SYK promoter region. A set of nested primers (CPG 1 and 2 and CpG 3 and 4) were specifically designed to amplify a 531 bp region from the 5 0 end of the Syk promoter CpG island extending into the first Syk exon. The resulting PCR product spans 28 different CG dinucleotides. The samples were only scored for the first 25 CG dinucleotides because of some sequencing ambiguities for the last three CG dinucleotides. The sequencing results from individual subcloned PCR products from several T-lineage leukemia cell lines, Jurkat, Molt 3, H-9, HuT 78 as well as the B-lineage leukemia cell line, Daudi and a control peripheral blood sample are shown in Figure 3 . Filled boxes represent a methylated cytosine (CG sequence in our analysis) in a CpG dinucleotide and unfilled boxes represent an unmethylated cytosine (TG sequence in our analysis). Both our peripheral blood control sample (PBC-1) and the B-lineage leukemia cell line, Daudi, showed little methylation of the 25 CpGs surveyed by this PCR analysis. However, there was a small amount of methylation of the first few 5 0 CpGs, suggesting that these form the 5 0 border of the hypomethylated CpG Island. However, a different result was seen in the Tlineage leukemia cell lines. In the human T-lineage leukemia cell line, Molt 3 cell line, nearly every CpG dinucleotide in each clone was methylated. The Syk promoter in HuT 78 and H9 also showed dense methylation, although slightly less than the Molt 3 cells. These two cell lines shared a similar overall methylation pattern, which is consistent with their clonal origin.
Jurkat cells showed an even more complex methylation pattern with some alleles showing dense methylation and others being largely unmethylated. There was a single nucleotide polymorphism (A/G) at position À534 relative to the start of HUMPTK (GenBank # L 28824) that we could use to distinguish the two Jurkat Syk alleles in our PCR subclones. All PCR clones containing a G at this position were heavily methylated, whereas some of those with an A at this position were densely methylated, whereas other clones were unmethylated.
Methylation-specific PCR (MSP) of the Syk promoter in human T-lineage leukemic cells
MSP confirmed the presence of dense methylation of the Syk promoter in human T-lineage leukemia cell lines. CpGWare software from Intergene (Purchase, NY, USA) was used to design primers for MSP of the Syk promoter. Initially, two MSP primer sets were designed to specifically amplify either methylated (m) or unmethylated (u) bisulfite-modified sequence. A third set of primers was also designed to amplify unmodified DNA and used to confirm that modification was complete. A few additional experiments were also performed with a nested MSP primer set (Yuan et al., 2001 ) that gave similar results. Amplification with either the methylated or unmethylated set of primers results in either the presence or absence of a PCR product depending on the methylation status of the CpG dinucleotides interrogated by that primer pair. The unmethylated (u) primer pair generates a PCR product of 156 bp, whereas the methylated (m) primer pair generates a 146 bp product. PCR products obtained with the two MSP primer sets, m and u, on bisulfitemodified DNA from two B-lineage leukemia cell lines, Ramos and Raji, one myeloid leukemia cell line, K562 and two T-lineage leukemia cell lines HuT 78 and H9, are shown in Figure 4 . In the two B-lineage leukemia cell lines, Ramos and Raji, and the myeloid leukemia cell line, K562, PCR products were only visible in the unmethylated lane. However, in the two T-lineage leukemic cell lines, HuT 78 and H9, prominent PCR products were obtained with the methylated primer set.
In the HuT 78 cell line, we also detected some product with the unmethylated primer set indicating that there were some unmethylated alleles in HuT 78, which we did not observe in our sequence analysis. Analysis of the methylation status of the Syk promoter in human thymocytes and peripheral blood T cells (both PHA stimulated and unstimulated) by either bisulfite sequencing or methylation PCR demonstrated little or no methylation of the Syk promoter in these cells, suggesting that methylation of the Syk promoter was unique to leukemic T-lineage lymphoid cells.
MSP of Syk promoter in primary T-lineage leukemia cells
DNA was extracted from bone marrow mononuclear cells from six patients diagnosed with T-lineage leukemia (T-All#'s 1-6). MSP analysis was performed on these samples using a nested PCR (Yuan et al., 2001 ). This nested PCR yields a band at 140 bp with a primer set specific for the unmethylated sequence and a band at 243 bp with a primer set specific for methylated sequence. DNA from T-lineage leukemia cell lines was used as PCR controls. While screening these six patients, we identified one T-lineage ALL patient who yielded a band with the methylated primer set and no band with the unmethylated primer set. MSP results from this patient (T-ALL# 3) as well as the five other T-lineage patients and the control cell lines, Molt 3, H9 and Jurkat, are shown in Figure 4 (Panel B). Again with this nested primer set we observed promoter methylation in Molt3, H9 and Jurkat, with Molt 3 and Jurkat also having a positive band with the unmethylated primer set. Thus in this set of Tlineage ALL patients, we observed a relatively low frequency 17% of Syk promoter methylation in comparison with that previously reported to be present in primary breast tumors (32%). However, these results do indicate that methylation of the Syk promoter may play a role in a subset of T-lineage ALL patients.
Correlation of Syk promoter methylation with low SYK protein expression in T-lineage ALL cell lines
We used Western blots and immunoprecipitation analysis to determine the level of SYK protein in the T-lineage leukemia cell lines. Results from three of these cell lines, HuT 78, H9 and Jurkat are shown in Figure 5 . Both Western blots and immunoprecipitation analysis revealed an absence of SYK protein expression in these cells. Jurkat cells contained detectable levels of the Syk mRNA by RT-PCR analysis, but little to no SYK protein was detected on Western blots. The other T-lineage leukemia cell lines, HuT 78 and H9, demonstrate no Syk message by RT-PCR analysis and no SYK protein by Western analysis. These results are in agreement with numerous studies demonstrating that promoter methylation blocks transcription, resulting in the absence of mRNA and protein expression.
Treatment of leukemic Molt 3 (immature T) cells and H9 (mature T) cells with the methylation inhibitor, 5
0 deaza-2 0 deoxycytosine, results in activation of SYK expression
Molt 3 cells and H9 cells were treated with the methylation inhibitor 5-Aza-2 0 deoxycytidine (5 azaCdR) at either 100 nm or 1 mm. After 3 days, RNA was extracted for RT-PCR analysis of Syk expression and amplification products were analysed by gel electrophoresis ( Figure 6 ). Formaldehyde gels of the RNA were used to determine the integrity and quantity of RNA used in PCR reaction. Equal amounts of RNA were used for all experiments ( Previous studies have demonstrated that cancer cell lines often show increased methylation of CpG islands (Flatau et al., 1983; Antequera et al., 1990; Smiraglia et al., 2001) . It has also been demonstrated that hypermethylation of tumor-suppressor CpG islands in tumors is preserved in their respective cell lines. Tumor cell lines have proven to be a valuable resource for the study of hypermethylation at a specific locus. Thy Syk promoter CpG island has previously been shown to be regulated by hypermethylation in invasive breast cancer. Our study extends this previous observation and Genomic DNA isolated from Ramos, Raji, K562, H9 and HuT 78 was bisulfite modified and amplified with a single round PCR primers specific for either methylated (M1U and M1L) or unmethylated (U1U and U1L) Syk promoter sequence. PCR products were subjected to electrophoresis on a 4% (3 : 1 NuSieve : LE) agarose gel and visualized by ethidium bromide staining. The methylation-specific primers yields a band at 146 bp and the unmethylated primer set yields a band at 156 bp. Panel b. Genomic DNA was isolated from the mononuclear cell fraction of bone marrow from six patients diagnosed with T-lineage acute lymphoblastic leukemia (T-ALL) and control T-lineage ALL cell lines, Molt3, H9 and Jurakat. The DNA was bisulfite modified and amplified in a nested MSP reaction adapted from Yuan et al. (2001) . After a preliminary amplification with first round PCR primer set (OF and OR), separate reactions for methylated promoter sequence (m) and unmethylated promoter sequence (u) were performed. The m-specific primer set yields a band at 243 bp and the u primer set yields a band at 140 bp prompts the hypothesis that silencing of the Syk promoter by methylation may also play role in Tlineage leukemia.
SYK expression is normally downregulated during T-cell development and it is possible that transient Syk promoter methylation may be involved in this process
However, the observed methylation of the Syk promoter CpG island in the mature T-lineage leukemia cell lines, Jurkat, HuT 78 and H9 that correspond to late stages of T-cell ontogeny, makes it unlikely that the observed methylation of the Syk promoter CpG island in MOLT-3 cells was merely because of their immature differentiation stage.
Our analysis of Syk promoter methylation in a Tlineage ALL patient suggests that Syk promoter methylation may play a role in a subset of T-lineage ALL. Further studies are necessary to determine the exact prevalence and clinical significance of Syk promoter methylation in T-lineage ALL. Since we have previously demonstrated aberrant Syk splicing in cases of pro-B lineage ALL (Goodman et al., 2001) , these results suggest that SYK may serve as a tumorsuppressor function in leukemia in addition to its previously described role as a tumor suppressor in breast cancer.
Materials and methods

Probes and probe labeling
Two Syk cDNA fragments, a nearly full-length 2.2 kb Syk cDNA (108-2265 bp) and a 502 bp ScaI fragment (1095-1597 bp), were used as probes as previously described (Goodman et al., 2001 ). An oligonucleotide probe, AA (5 0 -CGC CCG CCC TCG CCT CAC CTG GCG C-3 0 ), corresponding to the 5 0 untranslated region of HUMPTK (Accession # L 28824) was synthesized. This oligonucleotide probe was labeled with T-4 polynucleotide kinase and g 32 P-ATP (Amersham Biosciences, Piscataway, NJ, USA). The Syk cDNA fragments were labeled by random priming (Feinberg and Vogelstein, 1983) with Redi-Prime (Amersham Biosciences).
Cell lines and patients
Bone marrow samples were obtained from six patients with Tlineage ALL as well as from healthy volunteers. Mononuclear cell fractions containing >95% leukemic cells were isolated by centrifugation on Ficoll-Hypaque density gradients (Uckun et al., 1985 (Uckun et al., , 1997 . Diagnosis of T-lineage ALL was based on morphological, biochemical and immunological features of the (Uckun et al., 1991) were used in this study. The establishment, characterization and maintenance of these cell lines have been previously described in detail (Minowada et al., 1981) . The leukemic T cell lines used in this study include, HuT 78 (Gootenberg et al., 1981) , its clonal derivative H9 and Molt-3. HuT 78 and H9 were both derived from the peripheral blood of a patient with Sezary syndrome (Gootenberg et al., 1981; Mann et al., 1989) . The H9 cell line is a derivative of HuT 78 selected for permissiveness for HIV-1 replication. These cell lines have the properties of a mature human T cell with helper/inducer activity. Molt-3 cell line was established from cells of a patient with T-cell ALL in relapse who had received prior multidrug chemotherapy (Minowada et al., 1972) . K562 is a cell line derived from a 53-year-old female with chronic myelogenous leukemia (Lozzio and Lozzio, 1979; Koeffler and Golde, 1980; Lozzio et al., 1981) . Cells were cultured in RPMI supplemented with 20% fetal calf serum. Both patient and control tissue samples were obtained according to the guidelines of the Parker Hughes Institute Human Subjects Committee on the Use of Human Subjects.
Isolation of Syk promoter region
A P1 phage library (Sternberg, 1992; Neuhausen et al., 1994; Shepherd et al., 1994) from Research Genetics (Invitrogen, Carlsbad, CA, USA) was screened with an Syk cDNA probe and two positive P1 clones were isolated as previously described (Goodman et al., 2002) . Linear recircularized P1 plasmic was obtained by a modified alkaline lysis protocol (Birnboim and Doly, 1979) . Restriction fragments of the P1 plasmid that hybridized with a 5 0 Syk oligonucleotide probe, SYK AA (5 0 -TGGACACCTGCGCAGGTGTGTG-3 0 ), were gel eluted and subcloned into Bluescript KS + vector for sequence analysis. Two positive subclones, a 12 kb RI fragment and a 2.7 kb HindII fragment were completely sequenced by Tn7 transposon (Craig, 1996; Stellwagen and Craig, 1997 )-mediated sequence analysis (GPSt-1, Genome Priming System, New England Biolab). Cy 5 -labelled sequencing primers corresponding to the integrated transposon sequence were synthesized as follows.
Primer N: 5 0 -ACTTTATTGTCATAGTTTAGATCTAT-TTTG-3 0 and Primer S: 5 0 -ATAATCCTTAAAAACTCCATTTCCAC-CCCT-3 0 .
Dye-primer-labeled sequencing was performed with a ThermoSequenase Fluorescent Labelled Primer Cycle Sequencing Kit (Amersham Biosciences). Fluorescently labeled extension products were analysed on an automated ALF Express Sequencer (Amersham Biosciences).
Transient transfection
Daudi cells were transfected with 20 mg of Syk promoterluciferase plasmid and 8 mg of SV-b-galactosidase plasmid (Promega, Madison WI, USA), by electroporation (190V, 950 mF) with a BioRad Gene Pulser (BioRad laboratories, Richmond, CA, USA) in Cytomix buffer (120 nm KCL; 0.15 nm CaCl 2 , 10 nm K 2 HPO 4 , pH 7.6; 25 nm HEPES, pH 7.6; 2 nm EGTA, pH 7.6; 5 nm MgCl 2 ; pH adjusted with KOH). Shortly before use, freshly prepared ATP (2 nm; pH ¼ 7.6 adjusted with KOH) and glutathione (5 nm) were added to prevent leakage of the cytoplasmic components, to protect membranes against oxidation and to facilitate resealing of pores (van den Hoff et al., 1992) .
Luciferase assay
Cells were incubated for 10 min in 250 ml 'Reporter lysis buffer' (Promega, Madison WI, USA) and then scraped into plates. Cellular debris was removed by centrifugation and the supernatant was either stored frozen at À701C or else used directly in assay. An aliquot of the cell lysate was mixed with the Luciferase Assay reagent (Promega, Madison, WI, USA) that was maintained at or below room temperature. The Marker size in bp is indicated. Prior to RT reaction, total RNA was analysed for integrity and concentration on a denaturing formaldehyde gel (panels b and d). RNA millenium marker mix (Ambion, Austin, TX, USA) was used, 28S and 18S ribosomal bands are shown reaction was monitored in a luminometer (Turner Designs Model TD 20/20) , Promega, Madison WI, USA).
b-galactosidase assay
In order to control for transfection efficiency, whole cell lysates used in CAT or luciferase assays were normalized relative to the expression level of a cotransfected internal control plasmid encoding b-galactosidase (pSV-b-galactosidase, Promega, Madison, WI, USA). Reaction buffer diluent (100 nm sodium phosphate pH 7.5, 1 nm magnesium chloride, 5% SapphireIIt) was first equilibrated to room temperature. Galacton-Star substrate was freshly diluted 1 : 50 with reaction diluent buffer. Cell lysate (2-20 ml) in reporter lysis buffer (Promega) was added to 300 ml of a freshly prepared 1 : 50 dilution of the Galacton-Star substrate in luminometer tube and gently mixed. Samples were incubated for an hour at room temperature and light production measured using luminometer for 5 s.
Bisulfite sequence analysis
Bisulfite treatment of genomic DNA deaminates all unmethylated cytosines converting them to uracil residues, but leaves 5-methylcytosine intact. Subsequent PCR amplification of this modified DNA with primers specific for the modified sequence results in substitution of thymines for cytosine except for protected methylated cytosines. Subcloning and sequencing of the PCR product allows the direct determination of the methylation status of linked series of CpG dinucleotides from individual chromosomes. Bisulfite modification of DNA was performed with the CpGenome DNA Modification Kit according to the manufacturer's recommendations (Intergen Company, Purchase, NY, USA). After bisulfate modification, a set of nested primers was used to amplify the modified DNA. The following primers were used for first round PCR: CpG 1, GGGAGAAGGGTATTAGGTGGGTAT and CpG 2, CTCTTCCTCATTTAAACAACTTT. The PCR amplification reaction contained 1 mg of bisulfite-modified DNA, 200 mm dNTP, 1 mm primers, 50 nm MgCl 2 . The following PCR cycling conditions were used: an initial denaturation for 3 min at 961C, followed by addition of Taq polymerase and 38 cycles of 961C (20 s), 471C (20 s), 721C (1 min) with a final extension step at 721C for 5 min. The second round PCR reaction was performed with a 1/100 dilution of the first round. Primers for the second round were: CGP8 5 0 -TTTAGGGTTA-TAGGTTTAATTTATTTG-3 0 and CpG16 5 0 -CCCR-AAAC-TAAACAAAAATCRACT, where R ¼ purine, G or A. Cycling conditions were 961C for 3 min 1 Â ; 961C (20 s), 451C (20 s), 721C (1 min) for 30 cycles with a final extension at 721C for 5 min. PCR products were cloned into TOPO TA (Invitrogen, Carlsbad, CA, USA) for sequence analysis. Sequence analysis was performed as described above with Cy 5 -labeled T7 and reverse primers. The completeness of the modification reaction was monitored by demonstration of the presence of T's for all C's at non-CpG positions.
Methylation-specific PCR
DNA was modified by bisulfite treatment (as above). PCR was performed in a dedicated PCR hood, with dedicated PCR pipettes and plugged pipette tips. Genomic DNA was amplified with primers specific for WT: wild type (i.e.) unmodified DNA, M: methylated DNA and U: unmethylated DNA as shown:
WT1U: CGGCGGGAGGAGAGAGGCGCG WT1L: CTCCCAGTGTCGCGCCCCGCC U1L: GTTTGTATTTTTTTTTAGTGTTGTGTTTTGTT U1U: ACCCTTATCCAACAAAAAAAAAAAAACACA M1L: GTATTTTTTTTTAGTGTCGCGTTTCGTC M1U: CCTTATCCGACGAAAAAAAAAAAACGCG Cyling conditions: 951C, 10 min, 641C, 2 min (1 Â ); 721C, 30 s; 951C, 30 s, 641C, 30 s (30 cycles); 721C, 4 min, 41C hold with Taq polymerase and 2.5 mg primers (note that the annealing temperature was adjusted slightly for each primer set).
PCR screening of T-ALL patient samples was performed with a nested PCR reaction as described in Yuan et al. (2001) , since it was slightly more sensitive and robust than our initial single round PCR. The following primers were used for nested PCR reaction. Treatment with 5-aza-2 0 -deoxycytidine Cells were plated at 1 Â 10 5 in T75 flasks, treated 24 h later with either 1 Â 10 À6 m (1 mm) or 1Â 10 À7 m (100 nm) 5-aza-2 0 -deoxycytidine and incubated with drug for 3 days prior to harvest. Total RNA was isolated with TriPure (Roche, Indianapolis, IN, USA) reagent according to the manufacturer's recommendations. RNA was quantified by spectrophotometry. The integrity and relative concentration of RNA were confirmed by formaldehyde gel electrophoresis (Northern Max, Ambion, Austin, TX, USA) prior to reverse transcription. In brief, RNA was converted to first strand cDNA by reverse transcription with Superscript II (Life Technologies, Rockville, MD, USA). Primers SYK F (5 0 -AGGCCAAT-GACCCCGCTCTTA-3 0 ) and SYK R (5 0 -GGGTCTGGG-CCTTGTAGTAGTTTT-3 0 ). Cycling conditions were 941C, 3 min 1 Â , (941C, 30 s, 611C, 30 s, 721C, 1 min) 38 Â , (721C, 5 min, 41C, hold) 1 Â and SYK PCR was performed with Taq polymerase (Roche, Indianapolis, IN, USA).
Immunoprecipitation and Western blotting analysis
After harvesting and counting, the cells were washed in icecold PBS, lysed in ice-cold Triton X-100 lysis buffer (150 nm
